KRAB4 Inhibitors
Chemical inhibitors of KRAB4 can affect its function through various intracellular signaling pathways. Triptolide operates by hindering the NF-kB pathway, which plays a crucial role in gene transcription related to inflammation and cell survival. The suppression of NF-kB can result in decreased transcriptional activity on promoters regulated by this pathway, thereby potentially limiting the functional activity of KRAB4. Similarly, PD98059 and U0126, both inhibitors of MEK, can reduce the activity of the ERK pathway. Since KRAB4 may be regulated by the ERK pathway as part of its transcriptional modulation, diminished ERK activity due to these inhibitors can decrease KRAB4's functionality. LY294002 and Wortmannin, which inhibit the PI3K/Akt pathway, can alter the phosphorylation status of various proteins and transcription factors, potentially affecting KRAB4's regulatory actions.
Furthermore, SB203580, an inhibitor of p38 MAPK, impacts cellular responses to stress, which could influence KRAB4's regulatory network, especially under conditions where p38 MAPK is active. SP600125 targets the JNK pathway, another MAPK pathway, and by its inhibition, can decrease the functional activity of transcription factors that may regulate KRAB4. Rapamycin, an inhibitor of mTOR, affects the phosphorylation of key proteins involved in cell growth and metabolism, which might indirectly impact KRAB4 function. 5-Azacytidine, by inhibiting DNA methyltransferases, can cause DNA hypomethylation and potentially reduce KRAB4's DNA binding and, as a result, its repressive functions. Trichostatin A, a histone deacetylase inhibitor, can upregulate histone acetylation and possibly lead to the attenuation of KRAB4-mediated transcriptional repression. Chetomin disrupts the HIF pathway, which may impede KRAB4 if its activity is connected to this pathway. Lastly, MG132 prevents the degradation of ubiquitinated proteins, which could lead to an accumulation of transcriptional regulators that KRAB4 might normally target for degradation, thereby impeding KRAB4's regulatory role.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide, a diterpene triepoxide, inhibits the NF-kB pathway which is crucial for the expression of many genes involved in inflammation and cell survival. By inhibiting NF-kB, triptolide can suppress the transcriptional activity on promoters regulated by NF-kB, which may include those necessary for the functional activity of KRAB4. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of the ERK pathway. Since KRAB4 might be regulated by the ERK pathway as part of its role in transcriptional regulation, inhibition of MEK by PD98059 would down-regulate ERK activity and thus could reduce the functional engagement of KRAB4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway. The PI3K/Akt pathway is involved in the regulation of numerous transcription factors and could influence the transcriptional repression activities of KRAB4 through post-translational modifications or interaction with cofactors. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is an inhibitor of the p38 MAPK pathway, which is involved in cellular stress responses. Inhibition of p38 MAPK by SB203580 could therefore affect the regulatory network that controls the function of KRAB4, particularly under stress conditions where p38 MAPK activity is heightened. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of the ERK pathway. Since KRAB4 function may be modulated by the ERK pathway, inhibition of MEK1/2 by U0126 will lead to decreased ERK pathway activity and potentially reduce the functional activity of KRAB4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which is a key part of the PI3K/Akt pathway. By inhibiting this pathway, wortmannin can alter the phosphorylation status of various proteins and transcription factors that could be involved in the functional regulation of KRAB4. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. JNK influences the activity of a wide range of transcription factors, and its inhibition by SP600125 could, in turn, decrease the functional activity of KRAB4 if KRAB4 activity is regulated by transcription factors controlled by JNK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a central regulator of cell growth and metabolism. Inhibition of mTOR by rapamycin can affect the phosphorylation of S6 kinase and 4E-BP1, which can lead to changes in the translation of proteins that may regulate the function of KRAB4. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits DNA methyltransferases and can cause hypomethylation of DNA. As KRAB4 is a transcriptional repressor that could interact with methylated DNA sequences, the hypomethylation caused by 5-Azacytidine could lead to a reduction in KRAB4 binding to its target DNA, thereby inhibiting its function. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Since KRAB4 might recruit histone deacetylase complexes to exert its repressive functions, inhibition of these complexes by Trichostatin A could lead to an increase in histone acetylation and a concomitant decrease in KRAB4-mediated transcriptional repression. | ||||||